InflaRx N.V. (NASDAQ:IFRX) People

InflaRx N.V.

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Richard Brudnick
Other companies: Scholar Rock Holding Corporation (Director · Since at least Apr 6, 2023); Prime Medicine, Inc. (Chief Business Officer · Oct 19, 2022 – May 20, 2025 · Past); VolitionRx Limited (Director · Mar 25, 2021 – Jan 12, 2023 · Past); Codiak BioSciences Inc (See Remarks · Oct 13, 2020 – Feb 16, 2022 · Past); Bioverativ Inc (EVP, Business Development · Dec 22, 2016 – Mar 8, 2018 · Past)
Board Member · Since at least Mar 18, 2026
Anthony S Gibney
Other companies: Aura Biosciences, Inc. (See Remarks · Since at least May 13, 2025)
Director · Since at least Mar 18, 2026
Andreas KronbichlerDirector · Since at least Nov 3, 2026
Christian SchmidVP, Head of Legal Affairs & General Counsel · Since at least Nov 5, 2026
Daniel VetterSenior Director, Head of IT · Since at least Nov 5, 2026
David JayneBoard Member · Since at least Nov 3, 2026
Derval O’CarrollSenior Vice President, Global Head of Regulatory Affairs & Compliance · Since at least Mar 18, 2026
Gabriela AlperovichSenior Vice President & Global Head of Clinical Development · Since Oct 1, 2026
Hege HellstromBoard Member · Since at least Nov 5, 2026
Igor OrshanskiySenior Director, Head of Business Development · Since at least Nov 5, 2026
Jan MedinaVice President, Head of Investor Relations · Since at least Nov 3, 2026
Jonathan BarrattBoard Member · Since at least Nov 3, 2026
Jürgen FloegeBoard Member · Since at least Nov 3, 2026
Kirsten CremeringSenior Director, Head of Quality Assurance · Since at least Nov 5, 2026
Kofi BoatenVP, Head of Supply Quality & Clinical Trial Supplies · Since at least Nov 5, 2026
Maria HabelVP, Head of preclinical R&D and QC · Since at least Nov 5, 2026
Mark KublerDirector · Since at least Mar 18, 2026
med. Bernhard HellmichBoard Member · Since at least Nov 3, 2026
Ming-hui ZHAODirector · Since at least Nov 3, 2026
Nicolas FulpiusChairman of the Board · Since at least Mar 18, 2026
Niels C. RiedemannChief Executive Officer, Director · Since at least Mar 18, 2026
Peter A. MerkelBoard Member · Since at least Nov 3, 2026
Peter HurtSenior Director, Head of Drug Safety and Pharmacovigilance · Since at least Nov 5, 2026
Petra EßerVP, Head of Finance and Controlling · Since at least Nov 5, 2026
Renfeng GuoChief Scientific Officer, Director · Since at least Mar 18, 2026
Thomas TaapkenChief Financial Officer · Since at least Aug 6, 2026
Tony GibneyBoard Member, Head of Audit Committee · Since at least Nov 4, 2026